Mustang Bio, Inc.
MBIO
Price:
$0.2639
Market Cap:
$9.60M
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapi...[Read more]
Industry
Biotechnology
IPO Date
2017-08-22
Stock Exchange
NASDAQ
Ticker
MBIO
The ROE as of September 2024 (TTM) for Mustang Bio, Inc. (MBIO) is 1.40%
According to Mustang Bio, Inc.’s latest financial reports and current stock price. The company's current ROE is 1.40%. This represents a change of -179.58% compared to the average of -1763.08% of the last 4 quarters.
Mustang Bio, Inc. (MBIO) Historical ROE (quarterly & annually)
How has MBIO ROE performed in the past?
The mean historical ROE of Mustang Bio, Inc. over the last ten years is -4713.02%. The current 1.40% ROE has changed -129.77% with respect to the historical average. Over the past ten years (40 quarters), MBIO's ROE was at its highest in in the March 2024 quarter at 105.02%. The ROE was at its lowest in in the December 2023 quarter at -7004.88%.
Average
-4713.02%
Median
-63.14%
Minimum
-41952.85%
Maximum
108.16%
Mustang Bio, Inc. (MBIO) ROE by Quarter and Year
Discovering the peaks and valleys of Mustang Bio, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 24.51%
Maximum Annual ROE = 108.16%
Minimum Annual Increase = -148.19%
Minimum Annual ROE = -41952.85%
| Year | ROE | Change |
|---|---|---|
| 2023 | -41952.85% | 24.51% |
| 2022 | -170.49% | 199.05% |
| 2021 | -57.01% | -9.70% |
| 2020 | -63.14% | -32.28% |
| 2019 | -93.23% | 10.67% |
| 2018 | -84.25% | 61.10% |
| 2017 | -52.29% | 0.32% |
| 2016 | -52.13% | -148.19% |
Mustang Bio, Inc. (MBIO) Average ROE
How has MBIO ROE performed in the past?
The current ROE of Mustang Bio, Inc. (MBIO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-14060.12%
5-year avg
-8467.34%
10-year avg
-4713.02%
Mustang Bio, Inc. (MBIO) ROE vs. Peers
How is MBIO’s ROE compared to its peers?
Mustang Bio, Inc.’s ROE is less than Checkpoint Therapeutics, Inc. (292.43%), less than Reviva Pharmaceuticals Holdings, Inc. (7.96%), greater than Fortress Biotech, Inc. (-226.63%), greater than Kodiak Sciences Inc. (-77.23%), greater than Fortress Biotech, Inc. (-226.63%), greater than Achilles Therapeutics plc (-47.36%), greater than Aptose Biosciences Inc. (-5693.38%), greater than Aditxt, Inc. (-607.01%), greater than NeuroBo Pharmaceuticals, Inc. (-154.04%), greater than Dermata Therapeutics, Inc. (-197.44%), less than Unicycive Therapeutics, Inc. (294.74%), greater than Revelation Biosciences, Inc. (-243.91%), greater than Affimed N.V. (-155.57%), greater than Leap Therapeutics, Inc. (-98.01%), greater than Adaptimmune Therapeutics plc (-117.47%), greater than Corvus Pharmaceuticals, Inc. (-53.99%), less than Akari Therapeutics, Plc (1.04%), greater than Salarius Pharmaceuticals, Inc. (-148.64%), greater than Axcella Health Inc. (-3582.11%), greater than Magenta Therapeutics, Inc. (-61.71%), greater than Histogen Inc. (-108.33%),
| Company | ROE | Market cap |
|---|---|---|
| 292.43% | $105.48M | |
| 7.96% | $38.22M | |
| -226.63% | $45.96M | |
| -77.23% | $139.43M | |
| -226.63% | $45.17M | |
| -47.36% | $28.99M | |
| -5693.38% | $6.67M | |
| -607.01% | $2.47M | |
| -154.04% | $30.52M | |
| -197.44% | $2.78M | |
| 294.74% | $35.69M | |
| -243.91% | $1.50M | |
| -155.57% | $60.15M | |
| -98.01% | $115.18M | |
| -117.47% | $283.83M | |
| -53.99% | $378.44M | |
| 1.04% | $41.66M | |
| -148.64% | $2.28M | |
| -3582.11% | $0 | |
| -61.71% | $42.44M | |
| -108.33% | $929.11K |
Build a custom stock screener for Mustang Bio, Inc. (MBIO) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mustang Bio, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Mustang Bio, Inc. (MBIO) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Mustang Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Mustang Bio, Inc.'s ROE?
How is the ROE calculated for Mustang Bio, Inc. (MBIO)?
What is the highest ROE for Mustang Bio, Inc. (MBIO)?
What is the 3-year average ROE for Mustang Bio, Inc. (MBIO)?
What is the 5-year average ROE for Mustang Bio, Inc. (MBIO)?
How does the current ROE for Mustang Bio, Inc. (MBIO) compare to its historical average?